<DOC>
	<DOCNO>NCT00171301</DOCNO>
	<brief_summary>To allow patient treated deferasirox core study continue iron chelation therapy 2 year drug become locally commercially available . To evaluate long-term safety efficacy deferasirox measure treatment success , change liver iron content ( LIC ) change serum ferritin level . Safety mainly assess incidence adverse event ( AEs ) clinically significant lab parameter .</brief_summary>
	<brief_title>Extension Study Efficacy Safety Deferasirox Treatment Beta-thalassemia Patients With Transfusional Hemosiderosis ( Study Amended 2-year Duration )</brief_title>
	<detailed_description>Iron accumulation inevitable consequence chronic blood transfusion result serious complication absence chelation treatment remove excess iron . Deferasirox ( Exjade , ICL670 ) oral chelator high iron-binding potency selectivity . This extension study aim collect efficacy safety data 2 year treatment deferasirox extension study deferasirox become commercially available country center locate , whichever come first . The population comprise Î²-thalassemia patient transfusional hemosiderosis could satisfactorily treat deferoxamine deferiprone .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients complete plan 12month core study ( NCT00171171 ) Female patient reach menarche sexually active must use effective method contraception , must undergo clinically document total hysterectomy and/or ovariectomy , tubal ligation Written inform consent obtain patient and/or legal guardian patient 's behalf accordance national legislation Pregnant breast feeding patient . Patients consider investigator potentially unreliable and/or cooperative regard core study protocol , plan extension protocol</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Transfusional hemosiderosis</keyword>
	<keyword>Beta-thalassemia major</keyword>
	<keyword>Deferasirox</keyword>
	<keyword>iron overload</keyword>
	<keyword>rare anemia</keyword>
	<keyword>iron overload due transfusion</keyword>
</DOC>